Clinical Trial Update: A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety, pharmacokinetics, and anticancer activity of BAY3546828 (Actinium-225-macropa-pelgifatamab) in patients with advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• BAY3546828 (Actinium-225-macropa-pelgifatamab) (Actinium-225-macropa-pelgifatamab)

Snippet

Sponsor: Bayer | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING